Lee Beobyi, Kim Cheorl-Ho, Moon Sung-Kwon
Department of Anatomy, College of Medicine, Konkuk University, Chungju City, Chungbuk 380-701, South Korea.
FEBS Lett. 2006 Oct 2;580(22):5177-84. doi: 10.1016/j.febslet.2006.08.064. Epub 2006 Sep 5.
Honokiol, an active component in extracts of Magnolia officinalis, has been proposed to play a role in anti-inflammatory, antioxidant activity, anti-angiogenic and anti-tumor activity. Although honokiol has a variety of pharmacological effects on certain cell types, its effects on vascular smooth muscle cells (VSMC) are unclear. This issue was investigated in the present study, honokiol was found to inhibit cell viability and DNA synthesis in cultured VSMC. These inhibitory effects were associated with G1 cell cycle arrest. Treatment with honokiol blocks the cell cycle in the G1 phase, down-regulates the expression of cyclins and CDKs and up-regulates the expression of p21WAF1, a CDK inhibitor. While honokiol did not up-regulate p27, it caused an increase in the promoter activity of the p21WAF1 gene. Immunoblot and deletion analysis of the p21WAF1 promoter showed that honokiol induced the expression of p21WAF1 and that this expression was independent of the p53 pathway. Furthermore, the honokiol-mediated signaling pathway involved in VSMC growth inhibition was examined. Among the relevant pathways, honokiol induced a marked activation of p38 MAP kinase and JNK. The expression of dominant negative p38 MAP kinase and SB203580, a p38 MAP kinase specific inhibitor, blocked the expression of honokiol-dependent p38 MAP kinase and p21WAF1. Consistently, blockade of p38 MAPK kinase function reversed honokiol-induced VSMC proliferation and cell cycle proteins. These data demonstrate that the p38 MAP kinase pathway participates in p21WAF1 induction, subsequently leading to a decrease in the levels of cyclin D1/CDK4 and cyclin E/CDK2 complexes and honokiol-dependent VSMC growth inhibition. In conclusion, these findings concerning the molecular mechanisms of honokiol in VSMC provides a theoretical basis for clinical approaches to the use therapeutic agents in treating atherosclerosis.
厚朴酚是厚朴提取物中的一种活性成分,已被认为在抗炎、抗氧化、抗血管生成和抗肿瘤活性中发挥作用。尽管厚朴酚对某些细胞类型具有多种药理作用,但其对血管平滑肌细胞(VSMC)的作用尚不清楚。本研究对这一问题进行了探讨,发现厚朴酚可抑制培养的VSMC的细胞活力和DNA合成。这些抑制作用与G1期细胞周期阻滞有关。厚朴酚处理可使细胞周期阻滞在G1期,下调细胞周期蛋白和细胞周期蛋白依赖性激酶(CDK)的表达,并上调CDK抑制剂p21WAF1的表达。虽然厚朴酚没有上调p27,但它导致p21WAF1基因的启动子活性增加。对p21WAF1启动子的免疫印迹和缺失分析表明,厚朴酚诱导p21WAF1的表达,且这种表达与p53途径无关。此外,还研究了厚朴酚介导的参与VSMC生长抑制的信号通路。在相关通路中,厚朴酚诱导p38丝裂原活化蛋白激酶(MAP激酶)和JNK的显著激活。显性负性p38 MAP激酶和p38 MAP激酶特异性抑制剂SB203580的表达阻断了厚朴酚依赖性p38 MAP激酶和p21WAF1的表达。一致地,p38 MAPK激酶功能的阻断逆转了厚朴酚诱导的VSMC增殖和细胞周期蛋白。这些数据表明,p38 MAP激酶途径参与p21WAF1的诱导,随后导致细胞周期蛋白D1/CDK4和细胞周期蛋白E/CDK2复合物水平降低以及厚朴酚依赖性VSMC生长抑制。总之,这些关于厚朴酚在VSMC中的分子机制的发现为临床使用治疗药物治疗动脉粥样硬化提供了理论基础。